Innate Immune Responses to AAV Vectors - Wikidata - wikimedia - TriplyDB

Innate Immune Responses to AAV Vectors

Innate Immune Responses to AAV Vectors

http://www.wikidata.org/entity/Q37939843

about

Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B The interplay of post-translational modification and gene therapy Targeted approaches to induce immune tolerance for Pompe disease therapy Developments in the treatment of hemophilia B: focus on emerging gene therapy Exosome-associated AAV vector as a robust and convenient neuroscience tool Gene therapy for hemophilia Engineering antibody-like inhibitors to prevent and treat HIV-1 infection.Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network.The potential of adeno-associated viral vectors for gene delivery to muscle tissue.Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.Activation of the cellular unfolded protein response by recombinant adeno-associated virus vectors.Intraganglionic AAV6 results in efficient and long-term gene transfer to peripheral sensory nervous system in adult rats.Development of Gene Transfer for Induction of Antigen-specific Tolerance.Brain BLAQ: Post-hoc thick-section histochemistry for localizing optogenetic constructs in neurons and their distal terminals Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer Immobilization of FLAG-Tagged Recombinant Adeno-Associated Virus 2 onto Tissue Engineering Scaffolds for the Improvement of Transgene Delivery in Cell Transplants.Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV Gene Therapy for Duchenne muscular dystrophy.Genetic manipulation of myoblasts and a novel primary myosatellite cell culture system: comparing and optimizing approaches.RNA Interference Mediated Interleukin-1β Silencing in Inflamed Chondrocytes Decreases Target and Downstream Catabolic Responses.First-in-class small molecule potentiators of cancer virotherapy.IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression.AAV Vectors Vaccines Against Infectious Diseases.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model.Aerosol gene delivery using viral vectors and cationic carriers for in vivo lung cancer therapy.Viral vector-mediated transgenic cell therapy in regenerative medicine: safety of the process.The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer.In vivo induction of regulatory T cells for immune tolerance in hemophilia.Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells.Copackaging of multiple adeno-associated viral vectors in a single production step.Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer.Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells.rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study.Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of Treg induction upon hepatic AAV gene transfer.[Integration of AAV vectors and insertional mutagenesis].Gene therapy research at the frontiers of viral immunology.Immunity to CRISPR Cas9 and Cas12a therapeutics.

P2860

Q21245486-9D1434F4-9C33-4745-8E84-E1AF8EE9D7E6 Q26751281-91D9F289-B33B-4195-A456-9D719BDB8FC2 Q26767363-6D5B575D-7B9B-445E-8BDD-4AF9DAE9389E Q26823376-345CE35D-B2CC-48CB-80BA-92B977B033E3 Q27323458-807B9FFF-FF9C-4A2E-B787-72DF9685A2A6 Q28081911-0FAAD4A2-C660-41DA-9FAE-9F8D7E80F6E2 Q30490945-26801981-6314-4BD6-8810-A3D71E209D4F Q30525258-EF0FB0EE-D3EA-4751-8C3A-B163AB4C8BFC Q33902499-C8F4DE85-1B49-49B3-94B5-1658FB8C076A Q33938435-B9115E02-B2DD-4286-A099-05FEF88C9094 Q34370111-075DE103-5FBF-44CB-8C6C-49F25A450CD7 Q34548352-C5618E83-5429-495D-9D10-A08491F375C8 Q34684229-53FAC42E-1AB0-44CD-9919-CA472111F66B Q34794525-F6FC7759-C289-4AC7-82FF-C3EBE7BE1D5F Q35048066-C2AE86B0-84B3-4AB6-AD0B-4FA4106C6497 Q35561776-1646BDF1-3249-4208-8E60-4F9766F1B48F Q35649962-7FA6861F-28D1-4852-A7A5-8F5839A08809 Q36085401-309D9E7B-F6A6-43DE-B98C-3672BFA2826D Q36142477-4B33C05B-74C3-4115-95D0-1F6DFF75299A Q36295934-4A42BF01-69B8-4264-9D6B-81D692A38BA9 Q36572575-928D61A6-DFC1-4331-B79A-04372178F996 Q36747491-1CC14409-4953-425F-878E-4FF4462CB9AC Q36937304-13ABA2D1-9DB6-4885-A682-008A20EB1BFB Q36976498-E614D318-0297-4400-8070-F7DB842F7D40 Q37498000-5C0BA9FA-F66F-4465-80F0-ED4B040FB19C Q37621530-EA25C310-9315-4C62-8AD3-E14098491946 Q37686976-8A48BBB5-951A-4CF8-975A-C5E09BC47469 Q38271253-66E98503-47AE-4E5E-ADA9-CCC1DFE62631 Q38295640-5AE91245-5D4D-4237-B7E5-AE623423345F Q38539938-449D208C-A39A-4B54-AA2B-78A741B2C622 Q38574966-51D8BFED-D763-4BEB-B46E-30F660EDBCB6 Q38860287-95F89B11-6BDF-4E51-94FD-8A38FF356E27 Q38964154-F334642C-911E-4154-9004-81514D3C5AED Q40049410-6F9EE5E9-7239-44DC-B968-2BAF36ED2FA5 Q40216716-C4E618EA-8B1E-4FCD-BF90-9D686B9D2B55 Q40363311-CF8B99C0-2746-42A8-9228-420C0EFF9E94 Q40417058-BE4EF9FC-E1D7-4032-91E4-915D13F9591F Q40875310-EC2546E3-688B-441A-A7EF-9C3B7698E868 Q42227245-EB604635-1BB9-47DB-810D-E8C9BCDA34BD Q45873745-D15B5047-5F76-4558-8E46-2824124C849D

P2860

Innate Immune Responses to AAV Vectors

http://www.wikidata.org/entity/Q37939843

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Innate Immune Responses to AAV Vectors

@en

Innate Immune Responses to AAV Vectors.

@nl

type

label

Innate Immune Responses to AAV Vectors

@en

Innate Immune Responses to AAV Vectors.

@nl

prefLabel

Innate Immune Responses to AAV Vectors

@en

Innate Immune Responses to AAV Vectors.

@nl

P1433

Q37939843-3F04812C-EFE5-4CCE-B8EB-49FBD38D047D

P1476

Q37939843-64378EE2-D5B3-43E8-AF61-2C0866B9A456

P2093

Q37939843-55C375BB-6E10-4135-8751-D0F83379A06F

Q37939843-A0E188FB-7630-4365-8D6E-561EA9A403C9

Q37939843-B7A75A77-D8F0-4999-9B07-A94BAC1B4E95

Q37939843-C674C089-E07A-4755-93E0-06A8DF45813A

Q37939843-EF3B879F-B788-4A4D-B0C5-D5915AB55825

Q37939843-F0A6C91B-265B-4243-A0BA-74F335E58162

P2860

Q37939843-0252D261-029E-4C0D-A85B-F4F682C78AAB

Q37939843-0522A1D5-BB80-456E-99C5-4522F8F7C721

Q37939843-05936F32-CFEB-41D8-8339-FAB12179BCF1

Q37939843-09B8B15F-9C22-4E40-8590-D669FCCA0058

Q37939843-0EF35281-1417-47C2-A539-46065F002B25

Q37939843-14C2B60D-EA00-49B3-BF56-4717831B1FB3

Q37939843-1651A635-59A8-4C99-A5DA-9AA27CF11B6C

Q37939843-186AE9F3-D65B-41C5-8D1C-62122C0C0C9D

Q37939843-1D445B4E-E2FB-4298-A0E6-5ABB799B07EC

Q37939843-1DB9F5D6-EA56-484F-90F0-4B3D48972E33

P304

Q37939843-F57B47C1-7B47-4442-A2D8-70980CECEC1A

P31

Q37939843-81D153F3-DDB1-41C6-AE39-E7C5735CD6FD

P356

Q37939843-F74350BC-C7CD-4FA4-8586-F03E6D147A47

P478

Q37939843-A603A6D1-1B9B-44F2-8710-FD96BE78ECF6

P577

Q37939843-6FAE35FE-C75A-47AA-B99A-82C79275FF40

P5875

Q37939843-4EB39AB4-21D4-4669-A6E1-853E609EA601

P698

Q37939843-57E10DD8-1616-44EC-8FC6-7DC2C65DE557

P932

Q37939843-C7B19BF8-8F9A-4F58-BD6F-C1EC0485EAB0

P356

FMICB.2011.00194

P1433

Frontiers in Microbiology

P1476

Innate Immune Responses to AAV Vectors

@en

P2093

Arun Srivastava

http://www.w3.org/2001/XMLSchema#string

Ashley T Martino

http://www.w3.org/2001/XMLSchema#string

Geoffrey L Rogers

http://www.w3.org/2001/XMLSchema#string

George V Aslanidi

http://www.w3.org/2001/XMLSchema#string

Giridhara R Jayandharan

http://www.w3.org/2001/XMLSchema#string

Roland W Herzog

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial

Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors

Pathogen recognition and innate immunity

Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway

Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial

Toll-like receptors and their crosstalk with other innate receptors in infection and immunity

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response

Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity

P304

194

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FMICB.2011.00194

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51668922

http://www.w3.org/2001/XMLSchema#string

P698

21954398

http://www.w3.org/2001/XMLSchema#string

P932

3175613

http://www.w3.org/2001/XMLSchema#string